Another selective estrogen-receptor modulator for osteoporosis

New England Journal of Medicine

Volumn 362, Issue 8, 2010, Pages 752-754

  Becker, Carolyn ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; LASOFOXIFENE; PLACEBO; RALOXIFENE; TAMOXIFEN;

BONE DENSITY; BREAST CANCER; CLINICAL TRIAL; DRUG EFFECT; EDITORIAL; FOOD AND DRUG ADMINISTRATION; FRACTURE REDUCTION; FRAGILITY FRACTURE; HIP FRACTURE; HOT FLUSH; HUMAN; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK REDUCTION; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

EID: 77349116669     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0912847     Document Type: Editorial

References (11)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62.
2. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - results from a 3-year randomized clinical trial. JAMA 1999;282:637-45. [Erratum, JAMA 1999;282: 2124.]
3. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41. [Errata, JAMA 2006;296:2926, 2007;298:973.]
4. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37.
5. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010; 362:686-96.
6. Pfizer. Fablyn (lasofoxifene tartrate) 0.5 mg tablets (NDA 22-242): Reproductive Health Drugs Advisory Committee briefing document, September 8, 2008. (Accessed February 4, 2010, at http://www.fda.gov/ohrms/dockets/ac/08/ briefing/2008-4381b1-02-Pfizer.pdf.)
7. Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162:1140-3.
8. Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-24.
9. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-97. [Erratum, JAMA 1999;282:2124.]
10. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57.
11. Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D. Raloxifene and risk of stroke based on the Framingham stroke risk score. Am J Med 2009;122:754-61.